Promising results from clinical testing of erythropoietin (EPO) in multiple psychiatric diseases (Table 1) strengthen the hypothesis that it produces behavioral effects via central mechanisms associated with the neurobiology of cognition. This evidence concerns the gene EPO and psychiatric disorder.